Create Free Account

By creating account you will get access to hot stocks & personalised emails

Amplia Therapeutics Ltd

Healthcare AU ATX

0.06AUD
-(-%)

Last update at 2024-05-09T05:56:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.060.11
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -6.24244M -3.64422M -2.28100M -2.21900M -1.86996M
Minority interest - - - - -
Net income -6.29628M -3.64537M -2.28000M -2.21500M -1.86996M
Selling general administrative 2.41M 1.70M 1.35M 1.06M 1.11M
Selling and marketing expenses - - - - -
Gross profit - - - - -0.10400M
Reconciled depreciation 0.07M 0.00321M 0.00100M 0.00080M 0.00159M
Ebit -6.18859M -3.64307M -3.87400M -2.25700M -1.86996M
Ebitda -6.11522M -3.63986M -3.87300M -2.25600M -1.86837M
Depreciation and amortization 0.07M 0.00321M 0.00100M 0.00100M 0.00159M
Non operating income net other - - - - -
Operating income -6.18859M -3.64307M -3.87400M -2.25700M -1.94072M
Other operating expenses 7.48M 5.63M 3.87M 2.26M -
Interest expense 0.05M 0.00115M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.10M 0.00062M 0.00100M 0.00372M 0.02M
Net interest income 0.04M -0.00053M 0.00100M 0.00372M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M 0.00115M -0.00100M -0.00400M -
Total revenue 1.15M 1.98M 1.53M 0.03M 0.05M
Total operating expenses 7.48M 5.63M 3.87M 2.26M 1.94M
Cost of revenue - - - - 0.15M
Total other income expense net -0.05385M -0.00115M 1.59M 0.04M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -6.24244M -3.64422M -2.28100M -2.21947M -1.86996M
Net income applicable to common shares -6.24244M -3.64422M -2.28100M -2.21947M -1.86996M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 18.68M 24.48M 10.88M 9.12M 9.19M
Intangible assets 7.94M 7.94M 7.94M 7.94M 7.94M
Earning assets - - - - -
Other current assets 0.07M 0.05M 1.09M 0.07M 0.01M
Total liab 2.85M 2.64M 0.54M 0.51M 0.53M
Total stockholder equity 15.84M 21.85M 10.34M 8.61M 8.66M
Deferred long term liab - - - - -
Other current liab 2.40M 0.16M 0.00113M -0.00038M 0.03M
Common stock 151.53M 151.51M 136.55M 132.90M 130.95M
Capital stock 151.53M 151.51M 136.55M 132.90M 130.95M
Retained earnings -134.72442M -128.61845M -125.20600M -122.92500M -120.91800M
Other liab 0.00353M 0.00541M - - -
Good will - - - - -
Other assets 0.05M - - - -
Cash 9.26M 14.61M 1.85M 1.11M 1.24M
Cash and equivalents 7.98M 10.62M 1.85M 1.11M 1.24M
Total current liabilities 2.75M 0.53M 0.54M 0.51M 0.53M
Current deferred revenue -2.18115M -2.18115M - - -0.04390M
Net debt -6.98081M -12.50811M -1.84800M -1.10800M -1.23039M
Short term debt 2.18M 2.18M 0.00000M 0.00000M 0.01M
Short long term debt 2.11M - - - 0.01M
Short long term debt total 2.28M 2.10M 2.10M - 0.01M
Other stockholder equity -0.96903M -1.04165M -1.00711M -1.37129M -0.00052M
Property plant equipment 0.18M 0.01M 0.00500M 0.00080M 0.00160M
Total current assets 10.51M 16.53M 2.94M 1.18M 1.25M
Long term investments - - - - -
Net tangible assets 7.90M 13.91M 2.40M 0.67M 0.73M
Short term investments - - - - -
Net receivables 1.15M 1.84M 1.00M 0.03M 0.03M
Long term debt 0.00000M 2.10M - - -
Inventory 0.04M 0.03M -0.99931M -0.03457M -0.03442M
Accounts payable 0.35M 0.37M 0.54M 0.51M 0.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.96903M -1.04165M -1.00800M -1.37200M -1.36300M
Additional paid in capital - - - - -
Common stock total equity - - 136.55M 132.90M 130.95M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M -7.95085M 0.00040M -0.00027M -0.00047M
Deferred long term asset charges - - - - -
Non current assets total 8.18M 7.95M 7.94M 7.94M 7.94M
Capital lease obligations 0.17M - - - -
Long term debt total 0.09M 2.10M 0.00000M 0.00000M 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.05842M -0.01224M -0.00500M -0.01224M -0.00319M
Change to liabilities -0.01073M 0.00372M 0.03M -0.01624M 0.25M
Total cashflows from investing activities -0.05843M -0.02664M -0.00500M -0.00500M -0.00319M
Net borrowings -0.06465M 2.10M 2.10M 2.10M 2.10M
Total cash from financing activities -0.08422M 17.19M 3.66M 1.96M -0.01100M
Change to operating activities - - - - -
Net income -6.24244M -3.64422M -2.28115M -2.21947M -1.86996M
Change in cash -5.35190M 12.76M 0.74M -0.13300M -0.98800M
Begin period cash flow 14.61M 1.85M 1.11M 1.24M 2.23M
End period cash flow 9.26M 14.61M 1.85M 1.11M 1.24M
Total cash from operating activities -5.28969M -4.40202M -2.91626M -2.08798M -0.98735M
Issuance of capital stock 0.02M 16.27M 4.06M 2.15M -
Depreciation 0.07M 0.00321M 0.00067M 0.00080M 0.00159M
Other cashflows from investing activities -0.04079M -0.01224M -0.01224M -0.01224M -0.01224M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.68M -0.82543M -1.01837M -0.05865M 0.40M
Sale purchase of stock 0.02M -1.18186M -0.40200M -0.19200M -0.01100M
Other cashflows from financing activities -0.04080M 2.10M -0.00500M 0.00118M -2.14900M
Change to netincome 0.21M 0.06M -0.63600M 0.21M 0.23M
Capital expenditures 0.02M 0.01M 0.00500M 0.00500M 0.00300M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.68M -0.82543M -1.01837M -0.05865M -0.59455M
Stock based compensation 0.21M 0.06M 0.35M 0.20M -
Other non cash items 0.88M -0.76101M -0.63577M 0.13M 1.87M
Free cash flow -5.30732M -4.41642M -2.92125M -2.08798M -0.99035M

Fundamentals

  • Previous Close 0.06
  • Market Cap12.38M
  • Volume526717
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.51328M
  • Revenue TTM1.87M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.98M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATX
Amplia Therapeutics Ltd		 - -% 0.06 - - 8.83 1.12 - -3.0488
CSL
CSL Ltd		 -2.85 1.02% 277.05 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.07 0.46% 15.35 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.79 3.93% 19.31 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.04 3.54% 1.09 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Amplia Therapeutics Ltd

350 Queen Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director 1964
Mr. Hamish George Chief Financial Officer NA
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer NA
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology NA
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec. 1960
Dr. Frank Gelder Founding Scientist NA
Dr. James A. Taylor Ph.D. Trials Consultant 1961
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR Trials Consultant 1948
Dr. Benjamin M. Segal Clinical Consultant NA
Dr. Frederick E. Reno Ph.D. Toxicology Consultant NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.